Premium
Ten years of proteomics in multiple sclerosis
Author(s) -
Farias Alessandro S.,
Pradella Fernando,
Schmitt Andrea,
Santos Leonilda M. B.,
MartinsdeSouza Daniel
Publication year - 2014
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201300268
Subject(s) - multiple sclerosis , proteomics , cerebrospinal fluid , disease , biomarker , biomarker discovery , medicine , pathology , clinically isolated syndrome , demyelinating disease , demyelinating disorder , white matter , bioinformatics , magnetic resonance imaging , immunology , biology , biochemistry , radiology , gene
Multiple sclerosis, which is the most common cause of chronic neurological disability in young adults, is an inflammatory, demyelinating, and neurodegenerative disease of the CNS, which leads to the formation of multiple foci of demyelinated lesions in the white matter. The diagnosis is based currently on magnetic resonance image and evidence of dissemination in time and space. However, this could be facilitated if biomarkers were available to rule out other disorders with similar symptoms as well as to avoid cerebrospinal fluid analysis, which requires an invasive collection. Additionally, the molecular mechanisms of the disease are not completely elucidated, especially those related to the neurodegenerative aspects of the disease. The identification of biomarker candidates and molecular mechanisms of multiple sclerosis may be approached by proteomics. In the last 10 years, proteomic techniques have been applied in different biological samples ( CNS tissue, cerebrospinal fluid, and blood) from multiple sclerosis patients and in its experimental model. In this review, we summarize these data, presenting their value to the current knowledge of the disease mechanisms, as well as their importance in identifying biomarkers or treatment targets.